Nav: Home

Warwick signs cancer research partnership with China's Sun Yat-sen University

October 22, 2015

The University of Warwick and Sun Yat-sen University Cancer Center have signed a Memorandum of Understanding (MoU) to create a research partnership in cancer diagnosis and specialist cancer care.

The agreement, signed during the state visit to the UK of the President of the People's Republic of China, Mr Xi Jinping, focusses on four specific areas: nursing; digital pathology; anti-cancer drug development; and systems biology and precision medicine.

The MoU was signed by Professor Lawrence Young, Pro-Vice-Chancellor (academic planning and resources), University of Warwick, and Professor Chao-Nan Qian, Vice President of Sun Yat-sen University Cancer Center (SYSUCC). The signing took place at Mansion House, home and office of the Lord Mayor of the City of London) and was chaired by Parliamentary Under Secretary of State for Life Sciences, George Freeman MP.

Mr Freeman said both Britain and China have long been admired for producing some of the world's leading scientists and academics, whose advances have improved and saved the lives of millions of people suffering from serious diseases such as cancer.

He added: "Cancer is the number one killer of people in the UK and China and like many nations we are in hot pursuit to find an effective treatment. Which is why collaborations such as those being announced today between Warwick University and Sun Yat-Sen University Cancer Centre on training and research to co-develop anti-cancer treatments are so important."

Professor Lawrence Young, Pro-Vice Chancellor at the University of Warwick, said:

"We are delighted to be consolidating our collaboration with the Sun Yat-sen University Cancer Centre by signing this agreement today. This represents a milestone in the interaction between our two institutions and demonstrates the mutual benefit of our partnership.

"Working together to train future cancer specialists and to develop new anti-cancer treatments will significantly advance our mutual ambition to bring benefit to cancer patients in both China and the UK."

The memorandum will pave the way for the training of SYSUCC senior oncology nurses at the University of Warwick and of SYSUCC pathologists at Warwick and University Hospital Coventry and Warwickshire. Other developments include Warwick University advising on the development of a digital pathology system and related infrastructure at SYSUCC and related training aimed at capacity building. Joint research in anti-cancer drugs and systems biology and precision medicine is also included, alongside the training of SYSUCC researchers in these areas at Warwick..

Professor Sudhesh Kumar, Dean of Warwick Medical School, University of Warwick said:

"This new development addresses a range of key collaboration areas and will lead to advances in research programmes and training highly specialised clinical practitioners.

"Warwick Medical School makes a significant national and international contribution to education and research in health and has a number of pioneering research and study facilities which attract significant funding and enable collaborative research. This MoU is another example of how we are operating with other international higher education institutions to further our work."

The signing ceremony builds on earlier work between the two universities which initiated a number of significant developments, including a research programme to develop new anti-cancer drugs for one of the most common cancers in southern China. It also resulted in a leading digital pathologist from SYSUCC spending two months at the University Hospital Coventry and Warwickshire as part of an up-skilling programme led by Warwick.
The collaboration between the two higher education institutions has also begun to attract external support; the Royal Society National Science Foundation funding is supporting the development of new anti-cancer drugs and Sun Yat-sen University's chemistry department has received a prestigious Newton Fellowship to send one of their researchers to the University of Warwick to collaborate on new drug development.

University of Warwick

Related Cancer Articles:

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at     You can read The Transition Integrity Project's report here.